子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | The method of generating the base | JP22613487 | 1987-09-09 | JPH0810321B2 | 1996-01-31 | 卓 中村; 次郎 塚原; 嘉治 矢吹 |
| 102 | 15-deoxyspagarine suppository | JP20064391 | 1991-08-09 | JPH0648938A | 1994-02-22 | HIRAGA HIRONOBU; OKUMA TAKAAKI; UMEDA YOSHIHISA |
| PURPOSE:To provide a new suppository of 15-deoxyspagarine trihydrochloride betatype crystal. CONSTITUTION:The suppository achieving the high concentration of the 15- deoxyspagarine in blood and excellent in storage stability, etc., is obtained by preparing a combination of the 15-deoxyspagarine trihydrochloride beta type crystals with an oleophilic base agent solid at ordinary temperature into the suppository. | ||||||
| 103 | Antibiotics wap-5044c and wap-5044a, derivative from wap-5044 c treated with alginase, their production and use | JP29384391 | 1991-10-15 | JPH05105657A | 1993-04-27 | HIRATA HARUHISA; KATOU AZUSA; NAKATANI SEIGO; AIBA TAKESHI; OHASHI YOSHITAMI; GOTO MASAYOSHI |
| PURPOSE: To provide novel antibiotics useful for the theraspies of mycotic infectious diseases by Candida, Aspergillus, etc. CONSTITUTION: The objective antibiotics are expressed by formula I (X is of formula II or III) [i.e., WAP-5044A (X is of formula III) and WAP-5044C (X is of formula II)] or their salts. These compounds can be obtained by culturing, in a medium, microorganisms having productive ability of antibiotic(s) WAP-5044A and/or WAP-5044C [e.g. WAP-5044 strain (FERM P-12554)] to produce and accumulate the antibiotic(s) in the cultured product, followed by collecting it (them). A novel derivative, 2-amino-4-aminoxy-3-trans-butenoic acid of formula IV can be obtained by treating the antobiotic WAP-5044C with alginase. This compound of formula IV, which is unstable, can cause intramolecular rearrangement and intramolecular dehydration to effect ready conversion to β-cyanolamine of formula V. COPYRIGHT: (C)1993,JPO&Japio | ||||||
| 104 | JPH05389B2 - | JP977188 | 1988-01-21 | JPH05389B2 | 1993-01-05 | TEOFUIRU JIZETSUKU |
| 105 | Crystalline adithromycin dihydrate and manufacture | JP16863788 | 1988-07-06 | JPS6438096A | 1989-02-08 | DAGURASU JIYON MERUDORAMU AREN; KEBUIN MAIKERU NEBUYUU |
| 106 | 2-amino-5-hydroxy-4-pyrimidone | JP16763888 | 1988-07-05 | JPS6429367A | 1989-01-31 | FUREDERITSUKU JIYUUDOSON UOOKA; JIYON ROORENSU RAMATSUTEINA; BURAIAN TOOMASU ONIIRU |
| 107 | Manufacture of cimetidine | JP977188 | 1988-01-21 | JPS63192757A | 1988-08-10 | TEOFUIRU JIZETSUKU |
| 108 | Selective amidination of diamines | JP22624187 | 1987-09-09 | JPS6388166A | 1988-04-19 | ARZENO HUMBERTO B; MORGANS DAVID J JR |
| 109 | Manufacture of alpha-amino acid by catalytic reaction of co,hydroxyl compound and enamide | JP22565284 | 1984-10-26 | JPS60185753A | 1985-09-21 | MAAKU KURAAKU SESA; JIEIMUZU DEIBUITSUDO BAARINTON |
| 110 | Phenol derivative, manufacture and estrogenic controller containing same | JP8764884 | 1984-04-28 | JPS59219256A | 1984-12-10 | GURAHAMU CHIYAARUSU KUROORII; FUIRITSUPU NIIRU EDOWAAZU; JIYOOJI BEASUFUOODO HIRU; UIRIAMU ROBAATO PIRUGURIMU; BURAIAN SUTEIIRU TAITO; DEREKU UIRIAMU YANGU |
| 111 | Polyguanidine polymers and methods of use thereof | US16411703 | 2019-05-14 | US11013760B2 | 2021-05-25 | Alexander Pretsch; Michael Nagl; Christoph Wiesner; Ralph Hollaus; Miroslav Genov |
| Polyguanidines and methods of use thereof are described. In particular, polyguanidines of formula (I), formula (II), and formula (III) are described. The polyguanidines can be used to treat infection, such as bacterial, viral or fungal infection, and as an ex vivo microbial agent. | ||||||
| 112 | KETONE-BASED GAS ADSORBENT, GAS ADSORBENT COMPOSITION, AND DEODORANT PROCESSED GOODS | US15580399 | 2016-06-07 | US20180177906A1 | 2018-06-28 | Koji SUGIURA |
| The ketone-based gas adsorbent of the present invention is characterized by containing a primary amine compound. The primary amine compound is preferably at least one selected from the group consisting of hydrazide compounds, aminoguanidine compounds, and polyamines. | ||||||
| 113 | METHOD FOR PRODUCING POLYGUANIDINES | US15500772 | 2015-07-30 | US20170224723A1 | 2017-08-10 | Alexander PRETSCH; Michael NAGL; Christoph WIESNER; Ralph HOLLAUS; Miroslav GENOV |
| A method for preparing polycondensation products of guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl or allyl derivatives BA according to the following reaction scheme is provided: wherein X, R1, Gua, Y and Z are as defined in the specification. In the disclosed method, at least one benzyl or allyl derivative BA is subjected to a polycondensation reaction with excessive guanidine, aminoguanidine or diaminoguanidine G upon elimination of HX. | ||||||
| 114 | Long chain base sphingosine kinase inhibitors | US14377300 | 2013-02-08 | US09688668B2 | 2017-06-27 | Webster L. Santos; Kevin R. Lynch; Timothy L. Macdonald; Andrew Kennedy; Yugesh Kharel; Mithun Rajendra Raje; Joseph Houck |
| The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity. | ||||||
| 115 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | US14377300 | 2013-02-08 | US20150210675A1 | 2015-07-30 | Santos L. Webster; Kevin R. Lynch; Timothy L. Macdonald; Andrew Kennedy; Yugesh Kharel; Mithun Rajendra Raje; Joseph Houck |
| The invention relates to inhibitors of Sphingosine Kinase enzymatic activity, and methods of treating diseases and disorders by administering inhibitors of Sphingosine Kinase enzymatic activity. | ||||||
| 116 | Antimicrobial composition | US11389824 | 2006-03-27 | US08604073B2 | 2013-12-10 | Xintian Ming; Stephen J. Rothenburger |
| An antimicrobial composition comprising (a) a cationic surfactant derived from the condensation of fatty acids and esterified dibasic amino acids, such as lauric arginate and (b) an antibiotic, such as of β-lactam antibiotics, polypeptides, quinolones. The composition may be used as a stand alone antimicrobial formulation, or in combination with medical articles or medical devices. | ||||||
| 117 | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics | US12335198 | 2008-12-15 | US08153647B2 | 2012-04-10 | Jozsef Zsolt Bocskei; Gary McCort; Hans Matter; Henning Steinhagen; Bérangère Thiers |
| Disclosed are compounds according to formula (I): wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the compounds of formula (I). | ||||||
| 118 | Thiazole-based compound and inhibitor of T-type calcium channel containing the same | US12376599 | 2006-12-08 | US08143296B2 | 2012-03-27 | Hoh-Gyu Hahn; Dong-Yun Shin; Kee-Dal Nam |
| The present invention relates to novel thiazole-based compounds and T-type calcium channel inhibitors containing the compound. The T-type calcium channel inhibitor of the present invention is useful as a treating agent for disease associated with overexpression of T-type calcium channel. | ||||||
| 119 | ApoE mimetic agents | US12064117 | 2006-08-09 | US08063106B2 | 2011-11-22 | David J. Grainger; David John Fox |
| The invention provides low molecular weight apoE mimetic agents suitable for preparing a medicament to treat autoimmune, inflammatory or neurodegenerative disease, (X)a-L-(X)b(Formula (I)) wherein each X is a (potentially different) chemical moiety bearing a positive charge at physiological pH a and b are, independently, numbers between 3 and 6; and L is a linker. | ||||||
| 120 | Compositions of solution for sequencing reaction clean-up | US10524609 | 2003-08-25 | US07759055B2 | 2010-07-20 | Gabriels E. Joseph, Jr.; Masaharu Mabuchi |
| Wash solution and method for purifying sequencing reaction product. The wash solution comprises an effective amount of guanidine in a low ionic solution to reduce or eliminate the presence of dye terminators in a sequencing reaction product. In its method aspects, the present invention comprises the addition of the wash solution to the sequencing reaction product prior to filtration, followed by filtration to reduce or eliminate unincorporated dye terminators. The purified sequencing products can then be resuspended and transferred to an appropriate substrate for sequencing or further preparation. Dye blobs formed from unincorporated dye terminators no longer interfere with the electropherograms generated upon electrophoresis of the sample. | ||||||
QQ群二维码
意见反馈
意见反馈